Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Shanghai Fosun Pharmaceutical has received approval from the National Medical Products Administration for its new drug, Botulinum Toxin Type A, aimed at treating cervical dystonia in adults. This development follows their exclusive licensing agreement with Revance Therapeutics to import, use, and commercialize the drug in China, Hong Kong, and Macau. This approval marks a significant milestone for Fosun Pharma in expanding its portfolio in the pharmaceutical market.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
